Assess whether the primary endpoint will survive FDA scrutiny (adb0c2)

SITUATION The working file is advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module. CMC change-control owner in a rare-disease team designing a pediatric plan has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after a CMO 483 that maps to the NDA CMC module; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for CMC change-control owner in a rare-disease team designing a pediatric plan. 4. Advisory-committee question list that exposes a weak secondary endpoint is missing the fact CMC change-control owner needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in advisory-committee question list that exposes a weak secondary endpoint, then the action for CMC change-control owner - Hypothesis scorecard against advisory-committee question list that exposes a weak secondary endpoint: supported / rejected / untestable - Owner and next date for CMC change-control owner in a rare-disease team designing a pediatric plan - What changes the primary endpoint will if a CMO 483 that maps to the NDA CMC module is later withdrawn